Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis.
Access to transplantation
Allogeneic transplantation
Health services research
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
12
04
2019
revised:
06
06
2019
accepted:
11
06
2019
pubmed:
23
6
2019
medline:
31
7
2020
entrez:
23
6
2019
Statut:
ppublish
Résumé
Allogeneic hematopoietic cell transplantation (alloHCT) is offered in a limited number of medical centers and is associated with significant direct and indirect costs. The degree to which social and geographic barriers reduce access to alloHCT is unknown. Data from the Surveillance, Epidemiology and End Results Program (SEER) and the Center for International Blood and Marrow Transplant Research (CIBMTR) were integrated to determine the rate of unrelated donor (URD) alloHCT for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) performed between 2000 and 2010 in the 612 counties covered by SEER. The total incidence of AML, ALL, and MDS was determined using SEER, and the number of alloHCTs performed in the same time period and geographic area were determined using the CIBMTR database. We then determined which sociodemographic attributes influenced the rate of alloHCT (rural/urban status, median family size, percentage of residents below the poverty line, and percentage of minority race). In the entire cohort, higher levels of poverty were associated with lower rates of alloHCT (estimated rate ratio [ERR], .86 for a 10% increase in the percentage of the population below the poverty line; P < .01), whereas rural location was not (ERR, .87; P = .11). Thus, patients from areas with higher poverty rates diagnosed with ALL, AML, and MDS are less likely patients from wealthier counties to undergo URD alloHCT. There is need to better understand the reasons for this disparity and to encourage policy and advocacy efforts to improve access to medical care for all.
Identifiants
pubmed: 31228584
pii: S1083-8791(19)30376-3
doi: 10.1016/j.bbmt.2019.06.012
pmc: PMC7292490
mid: NIHMS1550137
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2086-2090Subventions
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier Inc.
Références
JAMA. 1998 Oct 7;280(13):1148-52
pubmed: 9777814
Bone Marrow Transplant. 2013 Mar;48(3):346-50
pubmed: 22863723
Bone Marrow Transplant. 2010 Jul;45(7):1167-73
pubmed: 20010868
JAMA. 2008 Jan 9;299(2):202-7
pubmed: 18182602
Am J Public Health. 2005 Jul;95(7):1149-55
pubmed: 15983270
JAMA. 2009 Jun 10;301(22):2349-61
pubmed: 19509382
Bone Marrow Transplant. 2016 Feb;51(2):241-8
pubmed: 26457909
Biol Blood Marrow Transplant. 2010 Aug;16(8):1070-5
pubmed: 20036337
N Engl J Med. 2000 Nov 23;343(21):1537-44, 2 p preceding 1537
pubmed: 11087884
Biol Blood Marrow Transplant. 2016 Jul;22(7):1319-1323
pubmed: 27013013
Biol Blood Marrow Transplant. 2010 Mar;16(3):368-75
pubmed: 19879951